~~<i id='7D5E4D0BA0'><strike id='7D5E4D0BA0'><tt id='7D5E4D0BA0'><pre id='7D5E4D0BA0'></pre></tt></strike></i>~~

Home» leisure time» explore

explore

author：focus 2025-09-27 14:40:03 Page View：37

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Truvian presents data for its desktop blood
Next article： Medical leaders decry Supreme Court decision on affirmative action

comprehensive

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

NIH trials fail to test meaningful long Covid therapies, experts say

AdobeMorethan2.5yearsaftertheNationalInstitutesofHealthreceiveda$1billionmandatefromCongresstostudya

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

A biotech analyst on neuroscience, placebo effect, not over

PaulMatteis(right),in2017withthen-colleaguesSeamusFernandez(farleft)GeoffreyPorges.AlexHogan/STATNEW